---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007574"
form_type: "8-K"
ticker: "SIGY"
cik: "0001642159"
company_name: "Sigyn Therapeutics, Inc."
filed_at: "2026-02-20T23:59:59+00:00"
generated_at: "2026-05-16T01:28:08.711969+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Sigyn Therapeutics raises ~$61.5k via three convertible notes at 35% discount

## Summary
- Entered three convertible note purchase agreements with Brio Capital, Osher Capital, and Lambda Venture Partners.
- Total principal amount of $72,222.21 (~$61,500 net proceeds) at 8% interest per annum.
- Notes convertible into common stock at a 35% discount to the lowest traded price over prior 20 trading days.
- No warrants issued; issuance exempt under Section 4(a)(2) as sales to sophisticated investors.
- Notes have a one-year maturity.

## SEC filing metadata
- accession: 0001493152-26-007574
- form_type: 8-K
- ticker: SIGY
- cik: 0001642159
- company_name: Sigyn Therapeutics, Inc.
- filed_at: 2026-02-20T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007574
- JSON: https://secwatch.observer/filing/0001493152-26-007574.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007574.txt

## Key facts
- Material Agreements
  Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Osher Capital Partners, LLC valued at $22,222.22 (effective 2026-02-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Osher Capital Partners, LLC
  - Value: $22,222.22
  - Effective: 2026-02-12
  source text: On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Osher Capital Partners, LLC, in the principal amount of $22,222.22
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm
- Material Agreements
  Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Brio Capital Master Fund, Ltd valued at $22,222.22 (effective 2026-02-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Brio Capital Master Fund, Ltd
  - Value: $22,222.22
  - Effective: 2026-02-12
  source text: On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Brio Capital Master Fund, Ltd, in the principal amount of $22,222.22
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm
- Material Agreements
  Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Lambda Venture Partners, LLC valued at $27,777.77 (effective 2026-02-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Lambda Venture Partners, LLC
  - Value: $27,777.77
  - Effective: 2026-02-06
  source text: On February 6, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Lambda Venture Partners, LLC, in the principal amount of $27,777.77
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.